Vasodilators for primary Raynaud's phenomenon Author Su, KYC, Sharma, M, Kim, HJ, Kaganov, E, Hughes, I, Abdeen, MH, Ng, JHK Published 2021 Journal Title Cochrane Database of Systematic Reviews Version Version of Record (VoR) DOI https://doi.org/10.1002/14651858.CD006687.pub4 Copyright Statement © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2021, Issue 5. Art. No.: CD006687.. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review. Downloaded from http://hdl.handle.net/10072/405317 Griffith Research Online https://research-repository.griffith.edu.au Cochrane Library Cochrane Database of Systematic Reviews Vasodilators for primary Raynaud's phenomenon (Review) Su KYC, Sharma M, Kim HJ, Kaganov E, Hughes I, Abdeen MH, Ng JHK Su KYC, Sharma M, Kim HJ, Kaganov E, Hughes I, Abdeen MH, Ng JH. Vasodilators for primary Raynaud's phenomenon. Cochrane Database of Systematic Reviews 2021, Issue 5. Art. No.: CD006687. DOI: 10.1002/14651858.CD006687.pub4. www.cochranelibrary.com Vasodilators for primary Raynaud's phenomenon (Review) Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Cochrane Trusted evidence. Informed decisions. Library Better health. Cochrane Database of Systematic Reviews T A B L E O F C O N T E N T S HEADER......................................................................................................................................................................................................... 1 ABSTRACT..................................................................................................................................................................................................... 1 PLAIN LANGUAGE SUMMARY....................................................................................................................................................................... 2 SUMMARY OF FINDINGS.............................................................................................................................................................................. 4 BACKGROUND.............................................................................................................................................................................................. 15 OBJECTIVES.................................................................................................................................................................................................. 16 METHODS..................................................................................................................................................................................................... 16 RESULTS........................................................................................................................................................................................................ 19 Figure 1.................................................................................................................................................................................................. 20 Figure 2.................................................................................................................................................................................................. 23 Figure 3.................................................................................................................................................................................................. 24 DISCUSSION.................................................................................................................................................................................................. 30 AUTHORS' CONCLUSIONS........................................................................................................................................................................... 34 ACKNOWLEDGEMENTS................................................................................................................................................................................ 34 REFERENCES................................................................................................................................................................................................ 35 CHARACTERISTICS OF STUDIES.................................................................................................................................................................. 41 DATA AND ANALYSES.................................................................................................................................................................................... 62 Analysis 1.1. Comparison 1: ACE inhibitor versus placebo, Outcome 1: Frequency of attacks per week......................................... 63 Analysis 1.2. Comparison 1: ACE inhibitor versus placebo, Outcome 2: Severity of symptoms....................................................... 64 Analysis 1.3. Comparison 1: ACE inhibitor versus placebo, Outcome 3: Duration of attacks........................................................... 64 Analysis 1.4. Comparison 1: ACE inhibitor versus placebo, Outcome 4: Capillaroscopic flow/skin perfusion by ultrasound......... 65 Analysis 1.5. Comparison 1: ACE inhibitor versus placebo, Outcome 5: Subjective assessment of improvement (10-cm visual 65 analogue scale)..................................................................................................................................................................................... Analysis 1.6. Comparison 1: ACE inhibitor versus placebo, Outcome 6: Adverse events.................................................................. 66 Analysis 2.1. Comparison 2: Alpha blockers versus placebo, Outcome 1: Frequency of attacks - buflomedil................................. 66 Analysis 2.2. Comparison 2: Alpha blockers versus placebo, Outcome 2: Severity of symptoms - buflomedil............................... 67 Analysis 2.3. Comparison 2: Alpha blockers versus placebo, Outcome 3: Adverse events - buflomedil.......................................... 67 Analysis 3.1. Comparison 3: Beraprost versus placebo, Outcome 1: Frequency of attacks per week.............................................. 67 Analysis 3.2. Comparison 3: Beraprost versus placebo, Outcome 2: Severity of attacks (1 to 4 scale)............................................ 68 Analysis 3.3. Comparison 3: Beraprost versus placebo, Outcome 3: Disability (100-mm visual analogue scale)............................ 68 Analysis 3.4. Comparison 3: Beraprost versus placebo, Outcome 4: Adverse events....................................................................... 68 Analysis 4.1. Comparison 4: Dazoxiben versus placebo, Outcome 1: Frequency of attacks per week............................................. 69 Analysis 5.1. Comparison 5: Ketanserin versus placebo, Outcome 1: Frequency of attacks per week............................................ 69 Analysis 5.2. Comparison 5: Ketanserin versus placebo, Outcome 2: Severity score (frequency of attacks/d × duration of 70 attacks)................................................................................................................................................................................................... Analysis 5.3. Comparison 5: Ketanserin versus placebo, Outcome 3: Duration of attacks per day (minutes)................................. 70 Analysis 5.4. Comparison 5: Ketanserin versus placebo, Outcome 4: Capillaroscopic flow/skin perfusion by ultrasound............. 70 Analysis 5.5. Comparison 5: Ketanserin versus placebo, Outcome 5: Adverse events...................................................................... 70 Analysis 6.1. Comparison 6: Nitrate/nitrate derivatives versus placebo, Outcome 1: Frequency of attacks................................... 71 Analysis 6.2. Comparison 6: Nitrate/nitrate derivatives versus placebo, Outcome 2: Severity of symptoms.................................. 71 Analysis 6.3. Comparison 6: Nitrate/nitrate derivatives versus placebo, Outcome 3: Capillaroscopic flow/skin perfusion by 72 ultrasound............................................................................................................................................................................................. Analysis 6.4. Comparison 6: Nitrate/nitrate derivatives versus placebo, Outcome 4: Raynaud Condition Score............................ 72 Analysis 7.1. Comparison 7: Phosphodiesterase inhibitors versus placebo, Outcome 1: Frequency of attacks per week.............. 73 Analysis 7.2. Comparison 7: Phosphodiesterase inhibitors versus placebo, Outcome 2: Severity of symptoms............................ 74 Analysis 7.3. Comparison 7: Phosphodiesterase inhibitors versus placebo, Outcome 3: Duration of attacks................................. 74 Analysis 7.4. Comparison 7: Phosphodiesterase inhibitors versus placebo, Outcome 4: Capillaroscopic flow/skin perfusion by 74 ultrasound............................................................................................................................................................................................. Analysis 7.5. Comparison 7: Phosphodiesterase